



*Dooley*

Office of Regulatory Policy  
HFD - 13  
5600 Fishers Lane  
Rockville, MD 20857

Attention: Claudia Grillo

MAILED

JUN 04 2004

REEXAM UNIT

The attached application for patent term extension of U.S. Patent No. 5,633,272 was filed on January 15, 2002, under 35 U.S.C. § 156.

The assistance of your Office is requested in confirming that the product identified in the application, BEXTRA™ (valdecoxib), has been subject to a regulatory review period within the meaning of 35 U.S.C. § 156(g) before its first commercial marketing or use and that the application for patent term extension was filed within the sixty-day period after the product was approved. Since a determination has not been made whether the patent in question claims a product which has been subject to the Federal Food, Drug and Cosmetic Act, or a method of manufacturing or use of such a product, this communication is NOT to be considered as notice which may be made in the future pursuant to 35 U.S.C. § 156(d)(2)(A).

Our review of the application to date indicates that the subject patent would be eligible for extension of the patent term under 35 U.S.C. § 156.

Inquiries regarding this communication should be directed to the undersigned at (703) 306-3159 (telephone) or (703)872-9411 (facsimile).

*Karin Ferriter*

Karin Ferriter  
Senior Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: James M. Warner  
Pharmacia Corporation - Patent Department  
Mail Zone 04E  
800 N. Lindbergh Blvd.  
St. Louis MI 63167

2004E-0319

LET